A New Listing and Fresh Funding
EDX Medical Group PLC (LSE:EDX), the Cambridge-based developer of digital diagnostic products, has had an eventful 2026. After announcing on 13 April that it planned to move its listing from the Aquis Exchange to AIM, the company began trading on AIM on 13 May 2026. In August it followed up with a share subscription raising approximately £2.7m to support the expansion of an employee health screening service.
What the Company Does
EDX Medical develops and distributes diagnostic tests and related services. Its activities include the distribution of prostate cancer tests, a range of tests awaiting regulatory approval and more complex diagnostic products. The company was originally listed on the Aquis Growth Market in 2021, renamed EDX Medical in 2022 following a reverse takeover by EDX Medical Ltd, and moved to the Apex segment in 2024. Its founder and largest shareholder is Professor Sir Chris Evans, who held about 33% of the company as of April 2026.
Latest Developments
The switch to AIM used the streamlined AIM Designated Market route, which meant no full admission document was required because of the company's time on Aquis. EDX said the move was intended to improve access to capital, liquidity and visibility with investors.
On 24 August 2026 the company announced a subscription of 19,378,563 new ordinary shares at 14p each, raising around £2.7m. Each subscription share carries warrants over two further ordinary shares, exercisable between July 2028 and July 2029. Following the fundraise, the company said it would have 431,373,146 ordinary shares in issue.
The proceeds are earmarked for the employee health screening service, which offers biomarker testing panels, general health checks, family history assessments and follow-up diagnostics where needed. EDX announced on 15 July 2026 that it had reached agreements in principle with three significant UK employers, with testing expected to begin in the final quarter of 2026, and said two further large companies had since approached it.
Financial Picture
In April the company indicated expected revenue of about £1.2m for the year to 31 March 2026, compared with £122,608 in the prior year. It later said that, after discussion with its auditors, £860,000 would be recognised in the current financial year because order processing ran beyond the year end. Cash at the end of March 2026 was about £2.9m. Sir Chris Evans has provided a working capital facility of up to £3.71m in addition to an existing £2.0m loan. The company has said it is unlikely to pay dividends in the short to medium term.
Sector and Index Context
As a recent arrival, EDX Medical joins a substantial group of early-stage healthcare and diagnostics businesses in the FTSE AIM All Share Index. Smaller diagnostics companies have often found funding difficult since the pandemic boom faded, and investors tend to look for evidence of recurring commercial revenue rather than pipeline promises alone.
Key Risks
The company remains at an early commercial stage, with small revenues relative to its funding needs. It relies on share raises and loans from its founder, and further dilution is possible. Some products await regulatory approval, and the employee screening agreements have yet to become definitive contracts. Concentration of ownership may also limit share liquidity.
What to Watch Next
Investors will be watching for conversion of the employer agreements into signed contracts, the start of screening activity in the fourth quarter, interim results for the six months to 30 September 2026 and any regulatory approvals for pending tests.
_11_18_2026_06_43_20_247880.jpg)





Please wait processing your request...